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Abstract
Although molecular classification brings interesting insights into breast cancer taxonomy, its implementation in daily clinical
care is questionable because of its expense and the information supplied in a single sample allocation is not sufficiently
reliable. New approaches, based on a panel of small molecules derived from the global or targeted analysis of metabolic
profiles of cells, have found a correlation between activation of de novo lipogenesis and poorer prognosis and shorter
disease-free survival for many tumors. We hypothesized that the lipid content of breast cancer cells might be a useful
indirect measure of a variety of functions coupled to breast cancer progression. Raman microspectroscopy was used to
characterize metabolism of breast cancer cells with different degrees of malignancy. Raman spectra from MDA-MB-435,
MDA-MB-468, MDA-MB-231, SKBR3, MCF7 and MCF10A cells were acquired with an InVia Raman microscope (Renishaw)
with a backscattered configuration. We used Principal Component Analysis and Partial Least Squares Discriminant Analyses
to assess the different profiling of the lipid composition of breast cancer cells. Characteristic bands related to lipid content
were found at 3014, 2935, 2890 and 2845 cm21, and related to lipid and protein content at 2940 cm21. A classificatory
model was generated which segregated metastatic cells and non-metastatic cells without basal-like phenotype with a
sensitivity of 90% and a specificity of 82.1%. Moreover, expression of SREBP-1c and ABCA1 genes validated the assignation
of the lipid phenotype of breast cancer cells. Indeed, changes in fatty acid unsaturation were related with the epithelial-to-
mesenchymal transition phenotype. Raman microspectroscopy is a promising technique for characterizing and classifying
the malignant phenotype of breast cancer cells on the basis of their lipid profiling. The algorithm for the discrimination of
metastatic ability is a first step towards stratifying breast cancer cells using this rapid and reagent-free tool.
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Introduction
Despite the reduction in mortality in breast cancer patients due
to earlier diagnosis and implementation of adjuvant chemo- and
hormone therapies, breast cancer is still the commonest cause of
cancer death in women worldwide [1]. Many factors and genes are
involved in the initiation of breast cancer, but mortality is due to
metastatic disease [2]. Patients who go on to develop life-
threatening metastases in the visceral tissues have a much higher
mortality rate and shortened life expectancy [3], [4].
Although the different biological behaviors and metastatic
patterns observed among the distinct breast cancer phenotypes
may suggest different mechanisms of invasion and metastasis, the
biological features of breast tumors have proven insufficient for a
comprehensive description of progression at first diagnosis, due to
the heterogeneity of the disease [5]. The datasets available use
specific genomic alterations to define subtypes of breast cancer [6].
However, the large number of genetic alterations present in tumor
cells complicates the discrimination between genes that are critical
for maintaining the disease state and those that are merely
coincidental [7]. Thus, although molecular classification provides
interesting insights into breast cancer taxonomy, its implementa-
tion in clinical care is questionable because it is too expensive to be
introduced in daily pathological diagnosis, and because the
information supplied is of insufficient reliability in single sample
allocation [8].
Many observations during the early period of cancer biology
research identified metabolic changes as common features of
cancerous tissue, such as the Warburg effect [9], [10]. New
approaches based on a panel of small molecules derived from the
global or targeted analysis of metabolic profiles of cells are being
developed to link cancer and altered metabolisms and to
characterize cancer cell–specific metabolisms [11], [12]. One of
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the clearest signals is the de novo production of fatty acids in tumor
cells associated with cancer progression, linked to an increased
need for membranes during rapid cell proliferation as a part of a
more general metabolic transformation, which provides cancer
cells with autonomy in terms of their supply of building blocks for
growth [13]. This metabolic change occurs as a result of common
oncogenic insults and is mediated by the activation of multiple
lipogenic enzymes affected at all levels of regulation, including
transcription, translation, protein stabilization and protein phos-
phorylation [14]–[][16]. Activation of de novo lipogenesis correlated
with a poorer prognosis and shorter disease-free survival for many
tumor types [17], [18]. A low ratio of TUFA/TFA has been
proposed as a molecular marker for these aggressive tumors, which
is called the lipogenic phenotype. The pathway that regulates
synthesis of fatty acid in normal and tumor cells shares identical
downstream elements including the SREBP-1c (transcriptional
regulator sterol regulatory element-binding protein-1) and LXR
(liver X receptor) [15], [19]. We hypothesized that the lipid
content of breast cancer cells might be an indirect measure of a
variety of functions coupled to breast cancer progression, and that
it could discriminate between different genetic features of breast
cancer cells, providing new information on the aggressiveness of
their phenotype.
To explore the lipid phenotype associated with breast cancer
malignancy we used Raman microspectroscopy (RS). RS is an
optical technique that utilizes molecular-specific, inelastic scatter-
ing of photons to interrogate biological material [20]. When a
sample is illuminated with an optical beam, a small fraction of the
photons is inelastically scattered by the intramolecular bonds
present. When this occurs, the photon donates energy to, or
receives energy from, the molecule, producing a change in the
molecule’s vibrational state. When it subsequently exits the
material, the photon has an altered energy level and, therefore,
an altered wavelength. This change in the photon’s energy is
known as the ‘Raman shift’ and is measured in wavenumbers.
Photons interacting with different biochemical bonds undergo
specific Raman shifts, which, considered together, form the
‘Raman spectrum’, a plot of intensity against the Raman shift
and a direct function of the molecular composition of the material
studied. When applied to biological tissue, the technique can
distinguish between pathologies based on the differences in their
biochemical makeup [21]. RS is a rapid, reagent-free and non-
destructive alternative for the analysis of cell biology systems [22].
Recent advances in Raman spectroscopy have given way to a wide
range of biomedical applications including cancer. Its ability to
detect variance related to DNA/RNA, proteins, and lipids have
made it an excellent tool for quantifying changes on the cellular
level, as well as differentiating between various cell fingerprints
over all the Raman spectral range. The collection of spectra can be
performed in vitro, ex vivo or in vivo without disrupting the cellular
environment [23]. This is a major advantage of Raman
spectroscopy, as most biological assays utilize chemical biomarkers
and often require conditions nonnative to the biological environ-
ment.
Usually, Raman spectra of biological samples are highly
complex, and so mathematical processing of the spectroscopic
data is required to obtain objective information. Multivariate
techniques reduce the dimensionality of the spectral data and
allow extraction of useful, objective and less complex information
[24], [25]. We used Principal Component Analysis (PCA) [26] and
Partial Least Squares Discriminant Analyses (PLS-DA) [27] to
assess the different profiling of the lipid composition of breast
cancer cells, which permitted differentiation of the lipogenic
phenotype according to the proportion of unsaturated fatty acids.
Moreover, PCA clearly distinguished cells with the epithelial-to-
mesenchymal transition (EMT) phenotype, which is widely linked
with breast cancer cell aggressiveness [28]. A discriminative model
was generated that segregates metastatic cells and non-metastatic
cells without basal-like phenotype with 90% sensitivity and 82.1%
specificity.
Materials and Methods
Cell culture and treatments
MDA-MB-435, MDA-MB-468, MDA-MB-321, SKBR3,
MCF7 and MCF10A cells were obtained from the American
Type Culture Collection. With the exception of MCF10A, all lines
were maintained under standard conditions in 1:1 (v/v) mixture of
DMEM and Ham F12 medium (DMEM/F12) supplemented with
10% fetal bovine serum (FBS), 1 mM pyruvate and 2 mM L-
glutamine in 5% CO2-95% air at 37uC in a humidified incubator.
MCF7 medium was supplemented with 0.01 mg/ml bovine
insulin. MCF10A was grown in DMEM/F12 medium supple-
mented with 5% horse serum, 1 mM pyruvate, 2 mM L-
glutamine, 0.01 mg/ml bovine insulin, 20 ng/ml EGF, 1 mg/ml
hydrocortisone and 100 ng/ml Tetanus toxine, in the same
incubator conditions described above. The treatment with the
LXR agonist T0901317 (Cayman Chemical Company, Michi-
gan), dissolved in DMSO, was performed at 2 mM final
concentration (controls were treated with DMSO at the same
concentration).
Immunocytochemistry and labelling of cells
For immunocytochemistry 86104 cells were seeded in 24 well-
plates containing cover slips and were fixed after 24 h using cold
methanol for 1 min. MCF10A in sparse conditions was obtained
with 86103 cells/well. Cells were washed three times with PBS1x
and treated with PBS1x-5% FBS for 30 min at room temperature.
The antibodies used were: Vimentin, mouse anti-human (Dako,
Atlanta); E-cadherin, mouse anti-human (BD Biosciences, NJ).
Antibodies were diluted 1:50 in PBS1x-1% FBS and used for 1 h
at room temperature. After three washes with PBS1x the
secondary antibody, Alexa 555 anti mouse IgG (Life technologies,
NY) was used diluted 1:1000 in PBS1x-1% FBS for 30 min at
room temperature. After three washes with PBS1x the cover slips
were mounted on slides using Vectashield (Vector laboratories,
Burlingame) with DAPI for nucleus visualization. Preparations
were analyzed with an Olympus BX60 fluorescence microscope
(Olympus, Japan), using the optimal filters and 406magnification.
For Nile Red and filipin staining 86104 cells were seeded in 24
well-plates containing coverslips and 24 h later cells were fixed
with 4% cold paraformaldehyde (PFA) in PBS1x for 15 min. After
fixing, cells were washed three times with PBS1x and stained with
Nile Red at a final concentration of 1 mg/ml for 1 h, or filipin at a
final concentration of 50 mg/ml for 2 h. Coverslips were then
mounted as described above (filipin staining without DAPI) and
analyzed with the confocal microscope (Leica TCS SP5, Wetzlar,
Germany) for Nile red and the Olympus BX60 fluorescence
microscope for filipin, with 406magnification.
Raman spectroscopy
For analysis, 36105 cells were used, and for MCF10A cells in
sparse conditions 36104 cells were used. For measurements in the
2820–3030 cm21 range, cells were seeded in Petri dishes with #0
coverglass (Mattek, Ashland, MA). After 24 h, cells were treated as
indicated for Nile red staining.
The Raman system Renishaw (Apply Innovation, Gloucester-
shire, UK) comprises a 514 nm laser that supplies an excitation
Raman Spectroscopy in Breast Cancer
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beam of about 10 mW power, which is focused onto the sample
via a microscope with 606 objective (Edmund, York, UK). The
same objective collects the scattered light from the sample and
directs it to the spectrometer. The spectrometer processes this
scattered light, by rejecting the unwanted portion and separating
the remainder into its constituent wavelengths. The Raman
spectrum is recorded on a deep depletion charge-coupled device
(CCD) detector (Renishaw RenCam). The recorded Raman
spectrum is digitized and displayed on a personal computer using
Renishaw WiRE software which allows the experimental param-
eters to be set.
The spectra were background subtracted with a custom-written
Labview program and the Gaussian fits for total fatty acids (TFA)
and total unsaturated fatty acids (TUFA) bands (2845 cm21 and
3015 cm21 respectively) were performed in Matlab allowing the
quantification of the two types of fatty acids in the cytoplasm [20].
Statistical analysis
Raman spectroscopy is a promising technique in biomedical
studies due to its non-invasive character and high specificity but
Micro-Raman spectra of biomedical samples are inherently
complex and weak. The use of multivariate analysis can improve
their applicability and extract the useful information that Raman
spectroscopy can provide to biomedicine.
In this study two multivariate techniques: Principal Component
Analysis (PCA) and Partial least square-discriminant analysis (PLS-
DA) were performed over the pre-processed Raman spectra in
order to evaluate the spectral differences between the cancerous
cell lines studied and to develop a model allowing their
discrimination and classification.
PCA operates in an unsupervised manner (no previous
knowledge of the samples under study is provided) and finds an
alternative set of coordinates, the principal components, (PCs) to
reduce the dimensionality and complexity of the data set. All the
spectra can then be explained in a much simpler fashion through a
small number of PCs that accounts for the maximum variance in
the data. In a PCA model, the matrix containing the set of spectra
(X) is decomposed into two smaller matrices (the scores (T) and the
loadings (P)): X = TPT+E where E is the residual explaining non-
useful information that could not be explained by the multiplica-
tion of the scores and the loadings for each spectrum. By plotting
the first Principal Components scores, relations between samples
(grouping) are revealed. In addition, plotting loadings as a function
of the wavenumbers reveal the most important diagnostic variables
or regions in the spectra related with the differences found in the
data set.
PLS-DA is a supervised classification method in which
knowledge of the sample (in our case, malignant or benign
phenotype) is included. PLS-DA employs the fundamental
principle of PCA but further rotates the component (latent
variables, LVs) by maximizing the covariance between the spectral
variation and group affinity so that the LVs explain the
diagnostically relevant variations rather than the most prominent
variations in the spectral dataset. In this study, the performance of
the PLS-DA diagnostic algorithm was validated using the venetian
blinds cross validation methodology with eight data splits. The
number of retained LVs was determined based on the minimal
root mean square error of cross validation (RMSECV) curves, and
finally six were taken.
Multivariate statistical analysis was performed using the PLS
toolbox (Eigenvector Research, Wenatchee, WA) in the Matlab
(Mathworks Inc., Natick, MA) programming environment. SPSS
(Statistical Package for the Social Sciences) for Windows was used
for the statistics of TFA and TUFA quantification. In all the
analyses, differences were considered significant when student’s
‘‘t’’ was lower than 0.05.
Before including Raman spectra in the multivariate statistical
techniques, correct preprocessing must be performed. In this case,
background subtraction was achieved with a Matlab and Labview
algorithm [29], and then normalization under all Raman spectra
was performed to correct for the different amplification in the
signal. This normalization can be based on the fact that the
spectral region used (the CH stretching region) can be considered
as the total biomass present in our confocal volume [30].
Real-time reverse transcription-PCR
Real-time reverse transcription-PCR (qRT-PCR) was per-
formed with gene-specific fluorescent SYBR Green probes
(Applied Biosystems, NY, USA) using a 7300 Real time PCR
system detection Instrument and the associated software (Applied
Biosystems), following the manufacturer’s instructions. Primers
were designed using Primer Express software (primer sequences
are available on request). We calculated relative changes by the
comparative CT method using cyclophilin A as the reference gene.
Each reaction was performed in triplicate.
Results and Discussion
The expression of lipid metabolic genes is correlated to
the metastatic ability of cells
The transcription factors SREBP-1c (transcriptional regulator
sterol regulatory element-binding protein-1) and LXR (liver X
receptor) maintain cholesterol homeostasis through complemen-
tary pathways of feedback inhibition and feed-forward activation
[15], [31], [32]. To assess their coordinated action in the lipid
phenotype of breast cancer cells, we explored the LXR pathways
in a set of breast cancer cells according to their malignant
phenotype including both non-metastatic and metastatic cells:
MCF7, which expressed hormone receptors like luminal A tumors;
SKBR3, a phenotype with amplifications of the ErbB2 oncogene;
MDA-MB-468, p53 mutated cells with basal-like phenotype; and
two different metastatic models: MDA-MB-435, with lung
metastasis tropism, and MDA-MB-231 with bone metastasis
tropism, both belonging to the basal-like phenotype (also called
post-EMT cells) [33]. We analyzed the expression of SREBP-1c,
gene target of LXR, and ABCA1, other direct LXR target gene
involved in cell cholesterol export [19]. Twenty-four hours after
treatment with 2 mM LXR agonist T0901317 (Figure 1A), the up
regulation of SREBP-1c was evident in the metastatic cells MDA-
MB-231 and MDA-MB-435 compared with non-metastatic cells:
the transcriptional induction of SREBP-1c was 20 times higher in
MDA-MB-231 and 17.4 times higher in MDA-MB-435. In
contrast, treatment with the agonist produced only moderate
increases in the expression of SREBP-1c in SKBR3 (2.9 times) and
MCF7 (3.6 times), and a decrease in MDA-MB-468 cells.
Moreover, the cholesterol related gene ABCA1 was increased in
MDA-MB-231 (6.8 fold) and MDA-MB-435 (8 fold) and
differently induced in non-metastatic cells (SKBR3 cells, 27 fold,
MCF-7, 2.4 fold, and MDA-MB-468, 1.3 fold). These results
showed the differences in regulation of lipid metabolism pathways
in breast cancer cells.
Like nutritional control, neoplastic lipogenesis is controlled
through the modulation of the expression and/or maturation
status of the transcription factor SREBP-1c, a crucial intermediate
of the pro- and anti-lipogenic actions of nutrients and hormones,
which stimulates fatty acid synthase transcription in normal and
malignant cells [32], [34]. In tumor cells, SREBP-1c expression
and/or maturation is constitutively driven by the aberrant
Raman Spectroscopy in Breast Cancer
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hyperactivation of these pathways in response to a variety of
oncogenic changes, including overproduction of growth factors
(GFs), ligand-dependent or independent hyperactivation of GF
receptors (GFRs), and loss of function of components of the
signalling cascade such as the phosphatase and tensin homologue
(PTEN), a potent tumor suppressor [35], [36].
SKBR3 cells, a classical ErbB2 amplified model, responded
against the LXR agonist with increased ABCA1 expression,
different to that of MDA-MB-468 cells which have two
populations with different degrees of EGFR expression [37],
displaying low response against the agonist. It is well known that
endogenous synthesized fatty acids increase the signal-to-noise
ratio in the HER1/HER2-driven progression of human breast
epithelial cells towards malignancy [13]. Malignant cells have
devised a mechanism to subvert the normal pathways for feedback
inhibition via the EGFRvIII and PI3K-dependent activation of
SREBP-1c [15]. SKBR3 overexpressed SREBP-1c at basal levels
by a factor of five with regard to MDA-MB-468 and metastatic
cells; therefore, LXR might respond to excess cellular cholesterol
by promoting ABCA1-dependent cholesterol efflux [31]. On the
other hand, in normal cells, PI3K activation is tightly controlled by
dephosphorylation of PIP3 by the phosphatase PTEN. Activity of
the pathway is deregulated in cancer through a variety of
mechanisms, including activating mutations in PI3K or PTEN
loss [38], [39]. Indeed, the role of cholesterol metabolism in cancer
Figure 1. Variability in lipid metabolic genes expression and FA composition in MDA-MB-231, MDA-MB-435, MDA-MB-468, MCF7
and SKBR3 cell lines analysed by Raman microspectroscopy. A) The gene expression of SREBP-1c and ABCA1 were examined after 24 h
treatment with the LXR agonist T0901317 2 mM compared to the basal conditions by RT and real-time PCR. The fold induction is represented over the
pointed line. Cyclophilin A gene was used for normalization. B) Simplistic representation of the progression status of breast cancer cells used in the
study: 1) MCF10A cells; 2) MCF7, SKBR3 and MDA-MB-468 and 3) MDA-MB-231 and MDA-MB-345. C) Above, brightfield image of MDA-MB-435 cells,
with an asterisk indicating the position of the measurements in the cytoplasm. 606magnification and 9 mW power were used. Down, fluorescence
microscopy image of MDA-MB-435 cells stained with Nile red. 406magnification was used. D) Measured raw Raman spectra of the cell lines where
the axes are intensity (in arbitrary units) versus Raman shift (cm21). MCF10A cells were also measured. The TFA (2845 cm21) and TUFA (3015 cm21)
bands are indicated with the arrows in the first spectra.
doi:10.1371/journal.pone.0046456.g001
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pathogenesis and its association with EGFR/PI3K signaling has
recently been described as a potential therapeutic target [15].
The inverse correlation between estrogen receptors in breast
tumors and genes involved in lipid storage is well known [40].
Indeed, MCF7 cells had the lowest induction of SREBP-1c and
ABCA1. In addition, the increased expression of SREBP-1c and
ABCA1 in the estrogen negative metastatic cell lines indicated that
both genes are functionally implicated in the most malignant
phenotype. Therefore, the pathogenesis of metastasis may include
the conjunction of both constitutive metabolic features: fatty acid
synthesis and cholesterol cell content.
The lipid phenotype characterized by Raman
microspectroscopy
To explore the lipid phenotype associated to breast cancer
malignancy we optimized the Raman microspectroscopy (RS)
system to acquire Raman spectra in the range of 2820–
3030 cm21, where TFA (2845 cm21) and TUFA (3015 cm21)
bands were located. In the analysis we included MCF10A cells as
benign breast tumor cells, unable to spread outside the basal
membrane, despite their basal-like phenotype (Figure 1B).
The cytoplasm lipids were measured by RS in a position near
the nucleus and outside the endoplasmic reticulum area, where the
Nile red staining showed major lipid concentration (see asterisk in
Figure 1C). Each spectrum line in Figure 1D represents the
Raman intensity versus the Raman shift measured in a single cell,
and illustrates the cell variability inside each cell line. The bands
corresponding to TFA and TUFA for individual cells were used to
quantify the TFA and the TUFA average content in each cell line
(Figure S1A and S1B). To obtain the relative quantities of
unsaturated fatty acids (% UFA) in each cell line, which indicate
the lipogenic phenotype, the values of individual cells followed by
the average of cell lines were calculated (Figure S1C). Low but
significant changes in the TFA bands intensities were found when
the cell lines were compared with the MCF10A cells (Student’s
‘‘t’’,0.0009). The TFA content was clearly highest in MDA-MB-
435 cells, followed by the MCF10A cells, and lowest in the SKBR3
cells. These results are in agreement with the increasing evidence
that lipid accumulation is a hallmark of aggressive cancer cells, and
is involved in the production of membranes for rapid cell
proliferation [41].
TUFA bands intensities were only significantly lower in MDA-
MB-468, SKBR3 and MCF7 cells when compared to MCF10A
cells (Student’s ‘‘t’’,0.04). Moreover, no significant differences
were found between MCF10A and the metastatic cells MDA-MB-
231 (Student’s ‘‘t’’ = 0.076) and MDA-MB-435 (Student’s
‘‘t’’ = 0.661) with regard to TUFA. The unsaturation ratio, and
not the TUFA value, is indicative of de novo lipogenesis and cell
malignancy. For this reason, the percentage of unsaturated fatty
acids in each cell line was calculated, but we did not observe
significant differences due to the high dispersion in the individual
cell values. The Student’s ‘‘t’’ scores for the cells compared to
MCF10A were: MDA-MB-435 = 0.179; MCF7 = 0.166; MDA-
MB-231 = 0.323; MDA-MB-468 = 0.148 and SKBR3 = 0.139.
Thus, the quantification of these two bands was not sensitive
enough to differentiate benign from malignant breast cancer cells.
The total amount of lipids was analyzed with an alternative
technique using Nile red staining (Figure S2). The red channel
showed mainly the membrane phospholipids (hydrophilic lipids)
and the green channel mainly the hydrophobic lipids (in yellow in
the merge image), which accumulated in the typical cytoplasm
storage vesicles derived from the endoplasmic reticulum compart-
ment (called lipid droplets). They contain mainly esterified
cholesterol and triglycerides [42]. The confocal images of lipids
showed similar results to the RS quantifications with the exception
of MDA-MB-468 cells, which showed the highest Nile red
intensity. As expected, this technique was less informative than
Raman for differentiating the cells. The green channel intensities
labeling the lipid droplets did not correspond to the TUFA
quantification obtained by Raman. MCF7 cells did not show lipid
droplets, but their RS quantification was similar to that of SKBR3
and MDA-MB-468 cells. The RS results might also lead us to
expect more droplets in MCF10A cells. The overestimation of
unsaturated lipid content in MCF7 and MCF10A cells using RS
may be due to differences in the lipid composition of the droplets
[41].
The idea that exacerbated lipogenesis provides immortalized
epithelial cells with a profound neoplastic growth and/or survival
advantage over those that maintain physiological levels of
endogenous fatty acid biosynthesis strongly suggests that some
lipogenic enzymes may work as metabolic intermediates of
oncogenesis by linking cellular anabolism and malignant transfor-
mation [43], [44]. Indeed, the level of fatty acid saturation
indicative of de novo lipogenesis decreased when LNCaP prostate
cancer cells were treated with soraphen A (a lipogenesis inhibitor)
[17].
To improve the information obtained with the lipid phenotype
measurements, we performed a PCA analysis using the 2820–
3030 cm21 spectral data to study the grouping and the
homogeneity of the sample distribution (Figure 2). PC1 and PC2
scores accounted for 47% and 39% respectively of the total
variance in the dataset. Raman band regions responsible for the
PC1 score discrimination were 3014, 2890 and 2848 cm21
(related to lipid content) and 2940 cm21 (related to lipid and
protein content). Raman band regions responsible for the PC2
score discrimination were 2846 cm21 (TFA) and 2935 cm21,
associated with the chain end –CH3 [45].
MCF7 and SKBR3 cells were grouped in the low PC2 region
and separated for high and low levels of the PC1 axis respectively.
In contrast, other cell lines like MCF10A and MDA-MB-435
appear to be more heterogeneous, spreading through a larger area
in the PC axes (Figure 2, left panel). Although Raman spectral
region 2900 to 3100 cm21 has been labeled the CH stretching
region [45] and therefore, contains bands common for many
biomolecules, we attempted to extract a hypothesis from the PCA
score plot. As lipids were included in both PC1 and PC2 loadings,
we interpret that SKBR3 and MCF7 had the lowest content.
MDA-MB-231 and MDA-MB-468 cells had intermediate lipid
content and MDA-MB-435 and MCF10A cells differed widely,
though it was always high. Our interpretation of the PC1 loading
was that it represents mainly TFA, and that lipid and protein cell
content were inversely correlated, because we had lipid bands in
positive and the 2940 cm21 band (which includes both lipids and
proteins) in negative. MCF7 and SKBR3 cells, with similar PC2
scores, had different PC1 values, suggesting different protein
content, higher in SKBR3.
The most prominent band included in the PC2 loading was
2935 cm21. No one substrate is clearly associated with the
2935 cm21 band due to the fact that many biomolecules contain –
CH3 side terminal groups. The 2846 cm21 band, also included in
PC2, corresponds to total fatty acids and we hypothesized a
contribution of cholesterol and cholesterol esters in the 2935 cm21
band, because it is a lipid with many –CH3 side terminal groups.
We also observed differences in the ABCA1 gene expression, and
differences in cholesterol have been associated to proliferation and
migration of breast cancer cells [40], [41], suggesting the
involvement of cholesterol in the malignant phenotype of the
cells studied.
Raman Spectroscopy in Breast Cancer
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We analyzed the cholesterol content of the cell lines using filipin
staining, which labels free (unesterified) cholesterol present in the
cytosol and membranes of cells. We found differences in the
content and distribution of free cholesterol between the cell lines.
MDA-MB-231, MDA-MB-468 and MDA-MB-435 cells presented
the highest cholesterol intensity, though with different distribu-
tions: in MDA-MB-231 and MDA-MB-468 it was accumulated in
large cytoplasm spots, whereas MDA-MB-435 cells mainly
presented cholesterol in the plasma membrane together with
some smaller spots in the cytosol (Figure S3). The levels of
cholesterol were also high in MCF10A but low in MCF7 cells.
SKBR3 cells had higher cholesterol content than expected, given
their localization in the PCA, but reinforcing our hypothesis that
their high ABCA1 gene expression occurs in response to an excess
in cholesterol content (see Figure 1A). Taken together, these results
suggested that cholesterol might be involved in the lipid differences
between metastatic and non-metastatic cells. Moreover, its
contribution in the PC2 loading may also include cholesterol
esters, not observed with filipin.
The lipid profiling of breast cancer cells distinguishes
metastatic ability from malignancy
In the second step, a PLS-DA was used to construct a
classification model. This is a supervised method, meaning that
prior knowledge of the class membership was included. First we
built a classification algorithm to discriminate between non-
metastatic non-basal-like (MCF7 and SKBR3) and metastatic
basal-like (MDA-MB-231 and MDA-MB-435) cell lines. Then, in
the ideal prediction model, the first group will have class 0 and the
second one class 1 (Figure 3). The PLS-DA model was carried out
over the pre-processed Raman spectra and a cross-validation was
performed in order to check the strength of the algorithm to
predict new samples. The method for cross-validation was
venetian blinds w/10 splits and the errors for the prediction and
cross validated model were RMSEC: 0.3 and RMSECV: 0.45
respectively, showing good stability for predicting new samples. A
good discrimination between metastatic and non-metastatic cell
lines was achieved with sensitivities and specificities of 92.5% and
97.4% for the calibration and 90% and 82.1% for the cross-
validation respectively. These results showed good accuracy in
Figure 2. PCA scores showing the cell variability present inside each cell line and between the different cell lines. Illustration of PCA
scores from MCF10A, MDA-MB-231, MDA-MB-435, MDA-MB-468, MCF7 and SKBR3 cell lines RS acquisition. SKBR3 cells are shown in the green circle
and MCF7 cells in the blue circle. MDA-MB-435 and MCF10A cells are the most dispersed in the plot. On the right, the loading plots for each Principal
Component, both related to fatty acid and protein content (TUFA: 3014 cm21; protein and lipid: 2940 cm21; TFA: 2871, 2890, 2846 and 2848 cm21;
-CH3: 2935 cm21). Percentages in the score plots represent the variance accounted for each PC.
doi:10.1371/journal.pone.0046456.g002
Figure 3. PLS-DA discriminative model using Raman micro-
spectroscopy spectra of non-metastatic (SKBR3 and MCF7) and
metastatic (MDA-MB-231 and MDA-MB-435) cell lines. PLSDA
classification algorithm, in which non-metastatic cells are predicted with
class 0 and metastatic cells with class 1. A threshold is assigned (red
line) corresponding to the best specificity and sensitivity parameters
that separate groups of cells. RMSECV is represented by the error bars.
A sensitivity of 90% and a specificity of 82.1% were achieved. Once the
model was built, MCF10A and MDA-MB-468 were included to predict
their membership. Seventy-five per cent of MCF10A and 40% of MDA-
MB-468 cells are related to the metastatic group.
doi:10.1371/journal.pone.0046456.g003
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discriminating metastatic ability of breast cancer cells, better than
those reported for the Raman spectral window (2,800–
3,100 cm21) comparing benign disease and breast cancer tissue
in vivo samples, which had specificity and sensitivity of 81.2 and
72.4, respectively [46].
We used the PLS-DA model to test the membership of
MCF10A and MDA-MB-468 cells, which were not included in
the groups (Figure 3). The result indicated that most of the
MCF10A cells were very similar to the metastatic group. Seventy-
five per cent of the MCF10A cells analyzed were predicted to
belong to the metastatic class (above the threshold). The rest of the
MCF10A cells were localised below the threshold. Following the
same criteria eight of the twenty MDA-MB-468 cells analyzed
(40%) were localized in the metastatic group and the rest in the
non-metastatic group. The PLS-DA model showed that MCF10A
and MDA-MB-468 cells had different basal-like phenotypes.
These results suggested that the classification algorithm might
discriminate two different basal-like phenotypes: MDA-MB-468
cells, common to a subgroup of MCF10A cells, and the MCF10A
cells, common to MDA-MB-231 and MDA-MB-435 metastatic
cells.
It has been described that MCF10A cells with basal-like
phenotype, which present many features of mesenchymal cancer
cell lines in sparse cultures, have intrinsic plasticity for undergoing
EMT, transition present in the most aggressive breast tumors with
a basal phenotype [28]. Since MCF10A cells were grown at low
confluence, we hypothesized that the similarities between
MCF10A and MDA-MB-435 cells in the PCA and between
MCF10A and the metastatic cells group in the PLS-DA might be
related to culture conditions. We performed Raman analysis in
sparse and in dense MCF10A cultures, and in cells growing at the
edge of dense cultures (Figure 4A). In the PCA (Figure 4B), PC1
had a prominent TUFA band contribution, and PC2 loading was
formed by three lipid bands: 3014, 2890 and 2845 cm21, and the
2935 cm21 band with inverse correlation. The PCA scores plot
clearly separated MCF10A and MDA-MB-435 cell lines: the
phenotype of the MDA-MB-435 cells was characterized by higher
lipid content (y axis) and lower TUFA (x axis). TUFA band
intensity (PC1, x axis) also distinguished between the MCF10A
Figure 4. Raman microspectroscopy and PCA differentiate the MCF10A cells grown in confluent and sparse conditions. A) MCF10A
microscopy images of the cells measured by RS in confluent and sparse conditions. Brightlight images were obtained with an inverted microscope
and 106 magnification. Arrows indicate the different areas that were measured by Raman (a: confluent; b: separate cells grown at the edge of
confluent cultures; c: sparse). B) PCA representation of MDA-MB-435 cells and MCF10A cells (grown in high confluence and in sparse conditions). PC 1
and 2 separate different groups of cell lines. MDA-MB-435 cells have higher PC2 scores, separated from the MCF10A. MCF10A grown in high
confluence are displaced from the ones grown in sparse conditions showing higher PC1 scores. Asterisk indicates the localization of the ‘‘lipogenic
phenotype’’ in the axis. PC1 and PC2 loadings are described down with the bands related to TFA (arrow head) and TUFA (arrow) indicated. The
percentage means the variance accounted for each PC. C) Immunofluorescence images of E-cadherin and vimentin proteins in both MCF10A culture
conditions. DAPI staining appears minimized inside each picture.
doi:10.1371/journal.pone.0046456.g004
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subtypes, being lower in the sparse area and higher in the
confluent area.
We also analyzed the EMT phenotype of MCF10A cells grown
in sparse and confluent conditions. As expected, like MDA-MB-
435, cells lost E-cadherin and expressed more vimentin in sparse
conditions (Figure 4C) than in confluence. These results confirmed
that the spectroscopical differences were secondary to phenotypic
changes and correlated well with malignancy; clearly the degree of
similarity between MDA-MB-435 and MCF10A cells depends
strongly on the culture conditions of MCF10A.
The expression in the set of breast cancer cells of E-cadherin,
CK18 and vimentin at the mRNA level, and E-cadherin and
vimentin at protein level as well, confirmed the close relationship
between the lipid phenotype and the EMT process (Figure 5).
MCF7 did not express vimentin protein and SKBR3 did so in less
than 5% of the cells (Figure 5B), similar to MDA-MB-468 cells.
These results suggested that in addition to metastatic ability the
PLS-DA model discriminated cells with basal-like phenotype that
undergo EMT (MCF10A) from basal-like cells with no EMT
(MDA-MB-468).
The combination of multivariate statistical techniques applied to
the Raman spectral data (PCA and PSL-DA analysis) provided a
powerful quantitative method to discriminate cancer phenotypes.
These mathematical methods used the whole range of the spectra
for the differentiation of the cells. Our results suggest that the lipid
phenotype of these cells is a signal of the proclivity to mesenchymal
transition related to the high aggressiveness and metastatic spread
[47]. EMT is an essential developmental process by which cells of
epithelial origin lose epithelial characteristics and polarity, and
acquire a mesenchymal phenotype with increased migratory
behavior. Thus, the characterization of this functional phenotype
of cancer cells with RS provides information on intercellular cell
adhesion, down-regulation of epithelial markers, up-regulation of
mesenchymal markers, acquisition of fibroblast-like (spindle)
morphology with cytoskeleton reorganization, increase in motility,
invasiveness, and metastatic capabilities [47]–[49]. The PSL-DA
model described discriminates luminal or HER-2 overexpressing
cells without EMT and post-EMT cells with a sensitivity of 90%
and a specificity of 82.1%. Aggressive cells with basal phenotype
(related to EMT plasticity) can also be differentiated, although it
may be necessary to include other spectral regions to increase the
sensitivity in the differentiation of metastatic and non-metastatic
basal-like cell phenotypes. Recently, it has been reported that the
analysis of human tumor gene expression profiles identifies triple
negative breast cancer subtypes with an overall false-positive rates
of 1.7%, 1.7%, and 0.9% for ER, PR, and HER2, respectively [50].
Breast cancer is a heterogeneous disease that includes a wide
range of histological subtypes and a diversity of clinical behaviors
and patient outcomes [51]. We used representative cell variants,
including different phenotypes of breast cancer cells: estrogen
receptor expression, ErbB2 amplification, p53 mutation and
aggressive metastasic. The molecular and cellular characterization
of their associated ‘lipid signatures’ by RS, combined with
multivariate statistical analysis, is a promising technique for
characterizing the malignant phenotype of breast cancer cells
and might provide a helpful adjunct to gene-expression profiling
or proteomics in the classification, diagnosis and prognosis of
human cancers. Using different spectral ranges of RS, similar
results have been obtained regarding the lower lipid content in
SKBR3 compared to MDA-MB-231 and -435 cells [52]. These
Figure 5. Epithelial and EMT marker gene expression in MCF7, SKBR3, MDA-MB-231, MDA-MB-468, MDA-MB-435 and MCF10A
cells. A) The gene expression of epithelial cell markers (E-cadherin, cytokeratin 18) and the mesenchymal cell marker vimentin were examined by RT
and real-time PCR using 200 ng of RNA. E-cadherin and CK18 are represented compared to the luminal MCF7 cell line expression and vimentin is
represented compared to the MDA-MB-231 cell line. Cyclophilin A gene was used to normalize gene expression. B) Immunofluorescence staining of
the epithelial E-cadherin and the mesenchymal vimentin markers in MCF7, MDA-MB-468, MCF10A, SKBR3, MDA-MB-231 and MDA-MB-435 cells. DAPI
staining appears minimized in each picture. 406magnification was used.
doi:10.1371/journal.pone.0046456.g005
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findings support the use of this technology in the study of the lipid
phenotype of cells, with possibilities to be used in experimental
tumors [46], [53] and in human samples to distinguish between
ductal carcinoma in situ and invasive ductal carcinoma of the
breast [54]. Serum samples have been used to discriminate
between breast cancer patients and healthy individuals; the bands
analyzed were statistically accepted as markers corresponding to
proteins, polysaccharides and phospholipids [55]. Moreover, the
identification of new spectral signatures expanding the RS window
may offer more accurate classification of cells for diagnostic
purposes, providing rapid, reagent-free and non-destructive
alternatives for the analysis of tumor samples.
Raman spectroscopy has shown promise for use as a clinical tool
for diagnosis of breast cancer. Optimization of spectral acquisition
times and spatial resolution for clinical use is an area which needs
further investigation. Studies of larger patient population samples
will be needed to establish comparisons between spectral makers
for breast cancer cells and pathological indicators that are used for
current diagnosis. Moreover, improvements on current data
analysis techniques, including the application of advanced data
mining methods, along with novel preprocessing techniques will
also be critical to introduce RS in the clinical practice.
Conclusions
Raman spectroscopy is a promising technique in biomedical
studies due to its non-invasive character and high specificity. The
lipid phenotype associated to breast cancer malignancy belongs to
Raman spectra adquired in the range of 2820–3030 cm21, where
TFA (2845 cm21) and TUFA (3015 cm21) bands were located.
The combination of multivariate statistical techniques, which use
the whole range of the spectra, applied to the Raman spectral data
(PCA and PSL-DA analysis) provided a powerful quantitative
method to discriminate cancer phenotypes. In addition, an
algorithm to differentiate metastatic from non metastatic and
non basal phenotype breast cancer cells was design using PLS-DA,
with 90% sensitivity and 82.1% specificity. Our results suggest that
the lipid phenotype of these cells is a signal of the proclivity to
mesenchymal transition related to the high aggressiveness and
metastatic spread, then the identification of new spectral signatures
expanding the RS window may offer more accurate classification
of cells for diagnostic purposes.
Supporting Information
Figure S1 Analysis of the lipid content in the breast
cancer cell lines using Raman microspectroscopy. A)
Total fatty acid (TFA) and B) total unsaturated fatty acid (TUFA)
Raman band intensity average in the cell lines is represented in
arbitrary units. C) Relative unsaturated fatty acid content is
represented as %. The average was calculated with the individual
cell ratio values. The lines and the p values (student’s ‘‘t’’) indicate
the significance between bars compared to the MCF10A values.
(TIF)
Figure S2 Analysis of the lipid content in the breast
cancer cell lines using Nile red staining and confocal
microscopy. Cells were fixed in 4% PFA and treated with Nile
red (1 mg/ml) for 1 h at room temperature and analysed as
indicated in material and methods. Hydrophilic fatty acids, mainly
phospholipids, are seen in the red channel. Hydrophobic fatty
acids, mainly cholesterol esters and triglycerides, are seen in the
merge image in yellow. DAPI staining labels the nuclei. 406
magnification was used.
(TIF)
Figure S3 Analysis of the cholesterol content in MCF7,
SKBR3, MDA-MB-231, MDA-MB-468, MDA-MB-435 and
MCF10A cells with filipin staining and fluorescence
microscopy. Cells were fixed in 4% PFA and treated with
filipin (50 mg/ml) for 2 h at room temperature and analyzed as
indicated in material and methods. Filipin labels free cholesterol
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